NICE recommends Ixekizumab as an option for treating active psoriatic arthritis in adult patients

Ixekizumab (Taltz) has been recommended by NICE for use as a treatment option for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs). The NICE guidance states that ixekizumab alone, or with methotrexate, is recommended for treating active psoriatic arthritis in adults, only if: It is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: The person has peripheral arthritis with three or more tender joints and three or more swollen joints, and The psoriatic arthritis has not responded to adequate trials of